Skip to main content

Table 2 Treatment details (n = 35)

From: Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated patients

Radiotherapy

 

Dose, Gy, median (range)

50 (48–64)

Fraction number, median (range)

22 (21–29)

Duration, days, median (range)

36 (30–53)

Chemotherapy

 

Weekly cycles, median (range)

6 (1–6)

 6 cycles

22

 5 cycles

7

 3 to 4 cycles

5

 1 to 2 cycles

1

Cisplatin (yes: no)

32:3

Docetaxel (yes: no)

26:8

Hyperthermia

 

Weekly cycles, median (range)

6 (4–6)

 6 cycles

31

 5 cycles

3

 4 cycles

1

  1. Values are number unless otherwise noted